Ardsley Advisory Partners’s Coherus Oncology CHRS Stock Holding History

Ardsley Advisory Partners’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-25,000	Closed	-$553K	–	144
2019 Q2	$553K	Sell	25,000 -25,000	-50%	-$434K	0.09%	89
2019 Q1	$682K	Buy	50,000 +35,000	+233%	+$467K	0.13%	69
2018 Q4	$136K	Hold	15,000	–	–	0.03%	92
2018 Q3	$248K	Hold	15,000	–	–	0.03%	133
2018 Q2	$210K	Sell	15,000 -15,000	-50%	-$215K	0.03%	142
2018 Q1	$332K	Buy	+30,000	New	+$328K	0.05%	123

Other funds holding CHRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Ardsley Advisory Partners's CHRS Position: Q3 2019 in Review

Ardsley Advisory Partners sold out of Coherus Oncology (CHRS) in Q3 2019, closing a stake of 25,000 shares — an estimated $553K sold.

Ardsley Advisory Partners first reported a position in CHRS in Q1 2018 and held it in 6 quarters. The position peaked at $682K in Q1 2019. 167 funds tracked by Wall St. Rank hold CHRS as of Q3 2019.

Ardsley Advisory Partners reported no remaining Coherus Oncology position as of Q3 2019 after selling out during the quarter.
Ardsley Advisory Partners sold 25,000 Coherus Oncology shares in Q3 2019, an estimated $553K.
Ardsley Advisory Partners first reported a position in Coherus Oncology in Q1 2018 and held it in 6 quarters.
Ardsley Advisory Partners's Coherus Oncology position peaked at $682K in Q1 2019.
167 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2019.

Based on Ardsley Advisory Partners's 13F filing for Q3 2019, filed 14 Nov 2019.